ClinicalTrials.gg
CompletedNCT05130970Updated Dec 13, 2024Results posted

Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of Garadacimab and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by CSL Behring. Completed at 47 sites in 11 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
85th of 188
81 · median 61
Started
2022
with 16 others
Phase 2
82 of 236
13 open now
Registered
168th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 85th largest by enrollment of the 188 interventional ones that give a count, is one of 17 that started in 2022, is one of 82 in phase 2, and was the 168th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic pulmonary fibrosis (IPF).

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 40 years of age
  • Documented diagnosis of IPF

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular disease, including myocardial infarction, unstable ischemic heart disease, congestive heart failure, or angina during the 6 months before screening
  • Sinoatrial or atrioventricular block, uncontrolled hypertension
  • Active bleeding or current clinically significant coagulopathy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Garadacimab

    Administered IV and SC

    Drug: Garadacimab

  • Placebo comparator
    Placebo

    Administered IV and SC

    Drug: Placebo

Interventions

  • Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.

    Also known as: Factor XIIa antagonist monoclonal antibody, CSL312

  • DrugPlacebo

    Participants received a matching placebo IV loading dose, followed by 3 SC doses.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent (TE) Serious Adverse Events (SAEs)

    A TE SAE is defined as an SAE reported at or after the start of the first administration of study treatment. A SAE is defined as any untoward medical occurrence that at any dose results in: death, life-threatening event, initial or prolongation of existing hospitalization, disability or incapacity, congenital anomaly or birth defect, or any other medically significant event.

    Time frame: Up to 22 weeks

  2. Percentage of Participants With TE SAEs

    A TE SAE is defined as an SAE reported at or after the start of the first administration of study treatment. A SAE is defined as any untoward medical occurrence that at any dose results in: death, life-threatening event, initial or prolongation of existing hospitalization, disability or incapacity, congenital anomaly or birth defect, or any other medically significant event

    Time frame: Up to 22 weeks

  3. Number of Participants With TE Adverse Events of Special Interests (AESIs)

    The following TEAEs were considered as AESIs: Bleeding events that were abnormal in the opinion of the Investigator, Thromboembolic events (non-systemic thrombosis \[e.g., localized thrombosis associated with vascular access\] was not considered an AESI), and Severe hypersensitivity including anaphylaxis.

    Time frame: Up to 22 weeks

  4. Percentage of Participants With TE-AESIs

    The following TEAEs were considered as AESIs: Bleeding events that were abnormal in the opinion of the Investigator, Thromboembolic events (non-systemic thrombosis \[e.g., localized thrombosis associated with vascular access\] was not considered an AESI), and Severe hypersensitivity including anaphylaxis.

    Time frame: Up to 22 weeks

  5. Number of Participants With Garadacimab Induced Anti Drug Antibodies (ADAs) in Plasma

    Time frame: At Day 36 and Day 92 after the first treatment

  6. Percentage of Participants With Garadacimab Induced ADAs in Plasma

    Time frame: At Day 36 and Day 92 after the first treatment

  7. Number of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as Adverse Events (AEs)

    Time frame: Up to 14 weeks after treatment

  8. Percentage of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as AEs

    Time frame: Up to 14 weeks after treatment

Secondary outcomes

  1. Trough Plasma Concentration (Ctrough) After SC Administration of Garadacimab

    Time frame: At Day 36 and Day 64

  2. Maximum Plasma Concentration (Cmax) (Last SC Dosing Interval Only) of Garadacimab

    Time frame: After dosing on Day 64

  3. Time to Maximum Plasma Concentration (Tmax) (Last SC Dosing Interval Only) of Garadacimab

    Time frame: After dosing on Day 64

  4. Area Under the Plasma Concentration-time Curve Over the Dose Interval (AUC0-tau) (Last SC Dosing Interval Only) of Garadacimab

    Time frame: After dosing on Day 64

  5. Ctrough After IV Administration of Garadacimab

    Time frame: At Day 8

  6. Cmax After IV Administration of Garadacimab

    Time frame: After dosing on Day 1

  7. Tmax After IV Administration of Garadacimab

    Time frame: After dosing on Day 1

  8. Mean Change From Baseline in FXIIa-mediated Kallikrein Activity

    Time frame: Baseline and at Day 92

  9. Mean Percentage of Baseline in FXIIa-mediated Kallikrein Activity

    Percent baseline is calculated by using the formula visit value / baseline value multiplied by 100, percent baseline is reported as percentage in the outcome measure.

    Time frame: Baseline and at Day 92

07

Results

Posted Dec 13, 2024

Participant flow

This study was conducted at 47 study sites in 11 countries (Australia, Austria, Belgium, Canada, Denmark, Germany, Italy, Poland, Spain, the United Kingdom \[UK\], and the United States of America \[USA\]). No participants from Italy were enrolled in the study.

Participant flow — Overall Study
MilestoneGaradacimabPlacebo
Started4041
Completed3836
Not completed25
Withdrew: Adverse event11
Withdrew: Death01
Withdrew: Lost to follow-up01
Withdrew: Physician decision01
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryNumber of Participants With Treatment-emergent (TE) Serious Adverse Events (SAEs)

A TE SAE is defined as an SAE reported at or after the start of the first administration of study treatment. A SAE is defined as any untoward medical occurrence that at any dose results in: death, life-threatening event, initial or prolongation of existing hospitalization, disability or incapacity, congenital anomaly or birth defect, or any other medically significant event.

Time frame:
Up to 22 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent (TE) Serious Adverse Events (SAEs)
ParticipantsGaradacimabPlacebo
Number of Participants With Treatment-emergent (TE) Serious Adverse Events (SAEs)52
PrimaryPercentage of Participants With TE SAEs

A TE SAE is defined as an SAE reported at or after the start of the first administration of study treatment. A SAE is defined as any untoward medical occurrence that at any dose results in: death, life-threatening event, initial or prolongation of existing hospitalization, disability or incapacity, congenital anomaly or birth defect, or any other medically significant event

Time frame:
Up to 22 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With TE SAEs
Percentage of participantsGaradacimabPlacebo
Percentage of Participants With TE SAEs12.54.9
PrimaryNumber of Participants With TE Adverse Events of Special Interests (AESIs)

The following TEAEs were considered as AESIs: Bleeding events that were abnormal in the opinion of the Investigator, Thromboembolic events (non-systemic thrombosis \[e.g., localized thrombosis associated with vascular access\] was not considered an AESI), and Severe hypersensitivity including anaphylaxis.

Time frame:
Up to 22 weeks
Reported as:
Count of participants · Participants
Number of Participants With TE Adverse Events of Special Interests (AESIs)
ParticipantsGaradacimabPlacebo
Number of Participants With TE Adverse Events of Special Interests (AESIs)20
PrimaryPercentage of Participants With TE-AESIs

The following TEAEs were considered as AESIs: Bleeding events that were abnormal in the opinion of the Investigator, Thromboembolic events (non-systemic thrombosis \[e.g., localized thrombosis associated with vascular access\] was not considered an AESI), and Severe hypersensitivity including anaphylaxis.

Time frame:
Up to 22 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With TE-AESIs
Percentage of participantsGaradacimabPlacebo
Percentage of Participants With TE-AESIs5.00
PrimaryNumber of Participants With Garadacimab Induced Anti Drug Antibodies (ADAs) in Plasma
Time frame:
At Day 36 and Day 92 after the first treatment
Reported as:
Count of participants · Participants
Number of Participants With Garadacimab Induced Anti Drug Antibodies (ADAs) in Plasma
ParticipantsGaradacimabPlacebo
At Day 3612
At Day 9211
PrimaryPercentage of Participants With Garadacimab Induced ADAs in Plasma
Time frame:
At Day 36 and Day 92 after the first treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With Garadacimab Induced ADAs in Plasma
Percentage of participantsGaradacimabPlacebo
At Day 362.65.4
At Day 922.62.8
PrimaryNumber of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as Adverse Events (AEs)
Time frame:
Up to 14 weeks after treatment
Reported as:
Count of participants · Participants
Number of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as Adverse Events (AEs)
ParticipantsGaradacimabPlacebo
Number of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as Adverse Events (AEs)00
PrimaryPercentage of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as AEs
Time frame:
Up to 14 weeks after treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as AEs
Percentage of participantsGaradacimabPlacebo
Percentage of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as AEs0.00.0
SecondaryTrough Plasma Concentration (Ctrough) After SC Administration of Garadacimab
Time frame:
At Day 36 and Day 64
Reported as:
Mean · Microgram/milliliter (ug/mL)
Trough Plasma Concentration (Ctrough) After SC Administration of Garadacimab
Microgram/milliliter (ug/mL)Garadacimab
At Day 3616.445 ± 6.0362
At Day 6417.123 ± 7.9383
SecondaryMaximum Plasma Concentration (Cmax) (Last SC Dosing Interval Only) of Garadacimab
Time frame:
After dosing on Day 64
Reported as:
Mean · ug/mL
Maximum Plasma Concentration (Cmax) (Last SC Dosing Interval Only) of Garadacimab
ug/mLGaradacimab
Maximum Plasma Concentration (Cmax) (Last SC Dosing Interval Only) of Garadacimab37.41 ± 15.507
SecondaryTime to Maximum Plasma Concentration (Tmax) (Last SC Dosing Interval Only) of Garadacimab
Time frame:
After dosing on Day 64
Reported as:
Median · Hours (h)
Time to Maximum Plasma Concentration (Tmax) (Last SC Dosing Interval Only) of Garadacimab
Hours (h)Garadacimab
Time to Maximum Plasma Concentration (Tmax) (Last SC Dosing Interval Only) of Garadacimab165.4585 (45.250 to 478.633)
SecondaryArea Under the Plasma Concentration-time Curve Over the Dose Interval (AUC0-tau) (Last SC Dosing Interval Only) of Garadacimab
Time frame:
After dosing on Day 64
Reported as:
Mean · h*ug/mL
Area Under the Plasma Concentration-time Curve Over the Dose Interval (AUC0-tau) (Last SC Dosing Interval Only) of Garadacimab
h*ug/mLGaradacimab
Area Under the Plasma Concentration-time Curve Over the Dose Interval (AUC0-tau) (Last SC Dosing Interval Only) of Garadacimab18094.6128 ± 6977.9036
SecondaryCtrough After IV Administration of Garadacimab
Time frame:
At Day 8
Reported as:
Mean · ug/mL
Ctrough After IV Administration of Garadacimab
ug/mLGaradacimab
Ctrough After IV Administration of Garadacimab18.6054 ± 7.9685
SecondaryCmax After IV Administration of Garadacimab
Time frame:
After dosing on Day 1
Reported as:
Mean · ug/mL
Cmax After IV Administration of Garadacimab
ug/mLGaradacimab
Cmax After IV Administration of Garadacimab79.636 ± 31.4406
SecondaryTmax After IV Administration of Garadacimab
Time frame:
After dosing on Day 1
Reported as:
Median · h
Tmax After IV Administration of Garadacimab
hGaradacimab
Tmax After IV Administration of Garadacimab0.1000 (0.017 to 0.967)
SecondaryMean Change From Baseline in FXIIa-mediated Kallikrein Activity
Time frame:
Baseline and at Day 92
Reported as:
Mean · Nanomoles/liter/minutes (nmol/L/mins)
Mean Change From Baseline in FXIIa-mediated Kallikrein Activity
Nanomoles/liter/minutes (nmol/L/mins)GaradacimabPlacebo
Mean Change From Baseline in FXIIa-mediated Kallikrein Activity-0.0258 ± 0.06570.0072 ± 0.0706
SecondaryMean Percentage of Baseline in FXIIa-mediated Kallikrein Activity

Percent baseline is calculated by using the formula visit value / baseline value multiplied by 100, percent baseline is reported as percentage in the outcome measure.

Time frame:
Baseline and at Day 92
Reported as:
Mean · Percent baseline
Mean Percentage of Baseline in FXIIa-mediated Kallikrein Activity
Percent baselineGaradacimabPlacebo
Mean Percentage of Baseline in FXIIa-mediated Kallikrein Activity129.56 ± 215.689124.83 ± 68.872

Adverse events

Collected over Up to 22 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Garadacimab1/40 (2.5%)5/40 (12.5%)18/40 (45%)
Placebo1/41 (2.4%)2/41 (4.9%)19/41 (46.3%)
Most frequent serious events
Most frequent serious events
EventGaradacimabPlacebo
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders3/400/41
Pancreatitis acuteGastrointestinal disorders1/400/41
PneumoniaInfections and infestations1/400/41
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/401/41
Pneumothorax spontaneousRespiratory, thoracic and mediastinal disorders0/401/41
COVID-19Infections and infestations0/401/41
Most frequent other events
Showing 10 of 15
Most frequent other events
EventGaradacimabPlacebo
DiarrhoeaGastrointestinal disorders2/405/41
CoughRespiratory, thoracic and mediastinal disorders2/405/41
DizzinessNervous system disorders2/404/41
DyspnoeaRespiratory, thoracic and mediastinal disorders1/404/41
FatigueGeneral disorders3/403/41
BronchitisInfections and infestations3/402/41
Urinary tract infectionInfections and infestations3/401/41
C-reactive protein increasedInvestigations1/403/41
Abdominal discomfortGastrointestinal disorders2/400/41
Non-cardiac chest painGeneral disorders2/401/41

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GaradacimabPlaceboTotal
<=18 years000
Between 18 and 65 years235
>=65 years383876
Age, Continuous
Age, Continuous(years)GaradacimabPlaceboTotal
Mean72.6 ± 6.1972.9 ± 6.1772.8 ± 6.14
Sex: Female, Male
Sex: Female, Male(Participants)GaradacimabPlaceboTotal
Female142135
Male262046
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GaradacimabPlaceboTotal
Hispanic or Latino112
Not Hispanic or Latino373976
Unknown or Not Reported213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GaradacimabPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White404080
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)GaradacimabPlaceboTotal
Canada101
Austria303
Belgium033
United States192140
Poland549
Denmark325
United Kingdom448
Australia101
Germany347
Spain134
08

Study locations

47 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35205, United States
  • Pulmonary Associates Clinical Trials AZ
    Phoenix, Arizona 85032, United States
  • National Institute of Clinical Research
    Huntington Beach, California 92647, United States
  • University of Southern California - Center for Advanced Lung Disease
    Los Angeles, California 90033, United States
  • University of California Irvine
    Orange, California 92868, United States
  • Meris Clinical Research
    Brandon, Florida 33511, United States
  • Lakes Research
    Miami Lakes, Florida 33014, United States
  • Reliant Medical Research
    Miami, Florida 33165, United States
  • US Associates in Research LLC
    Miami, Florida 33175, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Central Florida Pulmonary Group, PA
    Orlando, Florida 32803, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Jadestone Clinical Research
    Silver Spring, Maryland 20904, United States
  • Hannibal Clinic
    Hannibal, Missouri 63401, United States
  • Weill Cornell Medical Center
    New York, New York 10021, United States
  • Superior Clinical Research
    Smithfield, North Carolina 27577, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Temple University TMS
    Philadelphia, Pennsylvania 19140, United States
  • Clinical Trial Center of Middle Tennesse
    Franklin, Tennessee 37067, United States
  • Elite Medical Research
    Dallas, Texas 75230, United States
  • Southwest Family Medicine Associates
    Dallas, Texas 75235, United States
  • Baylor Scott and White Health - Advanced Lung Disease Specialists
    Dallas, Texas 75246, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Royal Adelaide Hospital
    Adelaide, 5000, Australia
  • Medizinische Univerität Graz
    Graz, 8036, Austria
  • Kepler Universitätsklinikum
    Linz, 4021, Austria
  • Universitair Ziekenhuis (UZ) Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire Sart Tilman
    Liège, 4000, Belgium
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N 4A6, Canada
  • Dr. Syed Anees Medicine Professional Corporation
    Windsor, Ontario N8X 1T3, Canada
  • Odense Universitetshospital - Lungemedicinsk Forskningsenhed
    Odense, 5000, Denmark
  • Fachkrankenhaus Coswig GmbH
    Coswig, 01640, Germany
  • Universitaetsklinikum Essen - Ruhrlandklinik (Westdeutsches Lungenzentrum)
    Essen, 45239, Germany
  • Medizinische Hochschule Hannover - Klinik für Pneumologie
    Hannover, 30625, Germany
  • Petrus Krankenhaus Wuppertal
    Wuppertal, 42283, Germany
  • Azienda Ospedaliera Universitaria Ospedali Riuniti Foggia
    Foggia, 71122, Italy
  • Centrum Medycyny Oddechowej Bialymstoku
    Białystok, 15-044, Poland
  • Twoja Przychodnia Centrum Medyczne Nowa Sol
    Nowa Sol, 67-100, Poland
  • Centrum Badań Klinicznych NZOZ
    Wrocław, 51-162, Poland
  • Giromed Institute, SLP
    Barcelona, 08006, Spain
  • Hospital Universitario Puerta del Mar (HUPM)
    Cadiz, 11009, Spain
  • The Churchill Hospital - Oxford University Hospitals NHS Trust
    Oxford, MD OX3 7LE, United Kingdom
  • Queen Elizabeth Hospital
    Birmingham, B15 2GW, United Kingdom
  • Altnagelvin Area Hospital
    Londonderry, BT47 6SB, United Kingdom
  • Manchester Univ NHS - Wythenshawe Hospital
    Manchester, M23 9LT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Jan 2024, 22 months.

Results were first posted in Dec 2024, 11 months after primary completion.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 22 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2021
First posted
Nov 23, 2021
StartActual
Feb 3, 2022
Primary completionActual
Jan 2, 2024
CompletionActual
Jan 2, 2024
Results first posted
Dec 13, 2024
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05130970
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Nov 23, 2021
Start date
Feb 3, 2022
Primary completion
Jan 2, 2024
Completion
Jan 2, 2024
Results posted
Dec 13, 2024
Last update
Dec 13, 2024

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garadacimab

Start the discussion